CC
PDLI

Courier Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Courier Capital’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,778
Closed -$97K – 306
2015
Q1 		$97K Buy
13,778
+1,724
+14% +$12.5K 0.02% 280
2014
Q4 		$93K Buy
12,054
+1,230
+11% +$9.73K 0.02% 279
2014
Q3 		$81K Buy
+10,824
New +$100K 0.02% 273

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Courier Capital's PDLI Position: Q2 2015 in Review

Courier Capital sold out of PDL BioPharma, Inc. (PDLI) in Q2 2015, closing a stake of 13,778 shares — an estimated $97K sold.

Courier Capital first reported a position in PDLI in Q3 2014 and held it in 3 quarters. The position peaked at $97K in Q1 2015. 204 funds tracked by Wall St. Rank hold PDLI as of Q2 2015.

  • Courier Capital reported no remaining PDL BioPharma, Inc. position as of Q2 2015 after selling out during the quarter.
  • Courier Capital sold 13,778 PDL BioPharma, Inc. shares in Q2 2015, an estimated $97K.
  • Courier Capital first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 3 quarters.
  • Courier Capital's PDL BioPharma, Inc. position peaked at $97K in Q1 2015.
  • 204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2015.

Based on Courier Capital's 13F filing for Q2 2015, filed 3 Aug 2015.